Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous HCMV-specific T-cell therapy for newly diagnosed glioblastoma
ACTRN12613000838718Phase 2Withdrawn
- Sponsor
- QIMR Berghofer Medical Research Institute
- Start
- Jan 2013
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous HCMV-specific T cells in glioblastoma (GBM), sponsored by QIMR Berghofer Medical Research Institute. Primary endpoints: Progression-free survival and Safety and tolerability. Planned start Jan 2013; status: withdrawn.
02
Drugs
autologous HCMV-specific T cells
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ACTRN12613000838718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000838718.